medigraphic.com
ISSN 1561-3119 (Electronic)

2022, Number 4

<< Back Next >>

Rev Cubana Pediatr 2022; 94 (4)

Impact of pneumococcal vaccine on the incidence and hospitalization of children with Community-Acquired Pneumonia

Alpiste CCF, Vela RJM

Language: Spanish
References: 19
Page: 1-16
PDF size: 354.14 Kb.


ABSTRACT

Introduction: Globally, 99% of pneumonia deaths are children under 5 years old. The World Health Organization recommends the inclusion of pneumococcal vaccines in internationally expanded childhood immunization programs to reduce annual deaths in this age group.
Objective: To evaluate the impact of pneumococcal vaccine on the incidence and hospitalization of children under 5 years of age with community-acquired pneumonia.
Methods: Systematic review of various scientific publications related to the subject. The search sources were PubMed, SciELO and Google Scholar. The key words were: "children", "pneumococcal vaccine" in combination with "community-acquired pneumonia" or "child", "pneumococcal vaccines" and "pneumonia, bacterial". Analytical articles published from January 1, 2017 to October 6, 2021 were selected. Articles that do not include an author or Digital Object Identifier System or refer to hospital or nosocomial pneumonias were excluded.
Analysis and synthesis of information: Of the 136 articles found, 125 were discarded for not meeting the inclusion and exclusion criteria, 4 articles remained for the theoretical basis and 7 articles for this review. Pneumococcal vaccine PCV 13 was found to decrease incidence by up to 22% and hospitalization rates by 35%.
Conclusion: Vaccination is a very effective health strategy to reduce this kind of diseases, which are preventable through immunization.


REFERENCES

  1. Katz SE, Williams DJ. Pediatric Community-Acquired Pneumonia in the United States. Infect Dis Clin North Am. 2018;32(1):47-63. DOI: 10.1016/j.idc.2017.11.002

  2. Organización Panamericana de la Salud. Neumococo. Washington, D. C.: OPS/OMS; 2019. [acceso 13/10/2021]. Disponible en: https://www.paho.org/es/temas/neumococo2.

  3. Organización Mundial de la Salud. Neumonía. Ginebra: OMS; 2021 [acceso 13/10/2021]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/pneumonia3.

  4. Alicino C, Paganino C, Orsi A, Astengo M, Trucchi C, Icardi G, et al. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis. Vaccine. 2017;35(43):5776-85. DOI: 10.1016/j.vaccine.2017.09.005

  5. Yun KW, Wallihan R, Juergensen A, Mejias A, Ramilo O. Community-Acquired Pneumonia in Children: Myths and Facts. Am J Perinatol. 2019;36(S 02):S54-7. DOI: 10.1055/s-0039-1691801

  6. Luna CM, Pulido L, Burgos D. ¿Why is the rate of pneumococcal pneumonia declining? Curr Opin Pulm Med. 2018;24(3):205-11. DOI:10.1097/MCP.0000000000000478

  7. Takeuchi N, Naito S, Ohkusu M, Abe K, Shizuno K, Takahashi Y, et al. Epidemiology of hospitalized paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunization programme in Japan. Epidemiol Infect. 2020;148:e91. DOI: 10.1017/S0950268820000813

  8. Zhang T, Zhang J, Shao X, Feng S, Xu X, Zheng B, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study. Vaccine. 2021;39(33):4620-7. DOI: 10.1016/j.vaccine.2021.06.075

  9. Jimenez Trujillo I, Lopez de Andres A, Hernandez-Barrera V, Martinez-Huedo MA, de Miguel-Diez J, Jimenez-Garcia R. Decrease in the incidence and in hospital mortality of community-acquired pneumonia among children in Spain (2001-2014). Vaccine. 2017;35(30):3733-40. DOI: 10.1016/j.vaccine.2017.05.055

  10. Noel G, Viudes G, Laporte R, Minodier P. Evaluation of the Impact of Pneumococcal Conjugate Vaccine on Pediatric Community-Acquired Pneumonia Using an Emergency Database System. J Pediatric Infect Dis Soc. 2017;6(2):129-33. DOI: 10.1093/jpids/piw019

  11. Ruvinsky RO, Rearte A, Kupervaser J, Gentile F, Haidar A, Cafure ME, et al. Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact. Rev Panam Salud Pública. 2018;42:e167. DOI: 10.26633/RPSP.2018.167

  12. Gönüllü E, Soysal A, Yildiz I, Aydemir G, Tunç T, Karaböcüoglu M. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children =5 years after its implementation into the national immunization program of Turkey. Hum Vaccin Immunother. 2020;16(10):2504-8. DOI: 10.1080/21645515.2020.1727212

  13. Alvarado S, Cavada G, Villena R, Wilhelm J, Budnik I, Lara C, et al. Efecto de la vacuna antineumocócica conjugada 10-valente en el área sur de Santiago de Chile, 2009-2015. Rev Panam Salud Pública. 2019;42:e155. DOI: 10.26633/rpsp.2018.155

  14. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children. NEJM. 2015;372(9):835-45. DOI: 10.1056/NEJMoa1405870

  15. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children. Thorax. 2011;66(Suppl 2):ii1-23. DOI:10.1136/thoraxjnl-2011-200598

  16. Casas Maldonado F, Alfageme Michavila I, Barchilón Cohen VS, Peis Redondo JI, Vargas Ortega DA. Recomendación de la vacuna antineumocócica en las enfermedades respiratorias crónicas. Semergen. 2014;40(6):313-25. DOI: 10.1016/j.semerg.2014.06.012

  17. Seguí Díaz M. Efecto del uso de la vacuna antineumocócica 13-valente en los niños (y adultos) americanos. Semergen. 2016;42(1):49-51. DOI: 10.1016/j.semerg.2015.04.009

  18. Bernaola E, Gil F, Herranz M, Gil-Setas A, Guevara M, Castilla J. Pneumococcal Vaccination and Pneumonia Associated With Pleural Effusion in a Pediatric Population. Pediatr Infect Dis J. 2018;37(4):e87-92. DOI: 10.1097/INF.0000000000001798

  19. Organización Panamericana de la Salud. La pandemia de COVID-19 causa un importante retroceso en la vacunación infantil, según se desprende de los nuevos datos publicados por la OMS y el UNICEF. Washington, D. C.: OPS/OMS; 2021 [acceso 16/06/2022]. Disponible en: https://www.paho.org/es/noticias/15-7-2021-pandemia-covid-19-causa-importante-retroceso-vacunacion-infantil-segun-se19.




2020     |     www.medigraphic.com